Given the results of inhibiting RBMS1 expression in mice through genetic interventions, along with the function of RBMS1 in hiPSC-CMs, there is substantial evidence to suggest that RBMS1 holds significant potential as a therapeutic target for the management of cardiac hypertrophy and heart failure. The gene discussed is RBMS1; the disease is cardiac hypertrophy.